Vanguard National Trust
IMNM icon

Vanguard National Trust’s Immunome IMNM Stock Holding History

Vanguard National Trust’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33K Hold
63
– – ﹤0.01% 741
2026
Q1 		$1.38K Buy
+63
New +$1.4K ﹤0.01% 695

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vanguard National Trust's IMNM Position: Q2 2026 in Review

Vanguard National Trust held its Immunome (IMNM) position steady in Q2 2026 at 63 shares worth $1.33K. The position accounts for ﹤0.01% of the portfolio, ranked #741.

Vanguard National Trust first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.38K in Q1 2026. 201 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Vanguard National Trust held 63 shares of Immunome worth $1.33K as of Q2 2026.
  • Vanguard National Trust left its Immunome share count unchanged in Q2 2026.
  • Immunome made up ﹤0.01% of Vanguard National Trust's portfolio in Q2 2026, its #741 holding.
  • Vanguard National Trust first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
  • Vanguard National Trust's Immunome position peaked at $1.38K in Q1 2026.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.